Have a personal or library account? Click to login
Outcome After Azacitidine Treatment in Patients with High-Risk Myeolodysplastic Syndrome, Chronic Myelomonocytic Leukemia Type 2 and Acute Myeloid Leukemia – A Single Center Experience (Preliminary Data) Cover

Outcome After Azacitidine Treatment in Patients with High-Risk Myeolodysplastic Syndrome, Chronic Myelomonocytic Leukemia Type 2 and Acute Myeloid Leukemia – A Single Center Experience (Preliminary Data)

Open Access
|Nov 2020

Authors

V. Varbanova

viktoriia1982@abv.bg

Clinic of Hematology, Military Medical Academy, Sofia, Bulgaria

A. Anastasova-Postadzhiyan

Clinic of Hematology, Military Medical Academy, Sofia, Bulgaria

A. Nedeva

Clinic of Hematology, Military Medical Academy, Sofia, Bulgaria

I. Nikolov

Clinic of Hematology, Military Medical Academy, Sofia, Bulgaria

I. Kindekov

Clinic of Hematology, Military Medical Academy, Sofia, Bulgaria

Y. Kuyumdzhieva

Clinic of Hematology, Military Medical Academy, Sofia, Bulgaria

N. Petkova

Clinic of Hematology, Military Medical Academy, Sofia, Bulgaria

E. Vikentieva

Laboratory of clinical immunology, Military Medical Academy, Sofia, Bulgaria

M. Lubomir

Laboratory of Cytogenetics and Molecular Biology, Military Medical Academy – Sofia, Bulgaria

J. Raynov

Clinic of Hematology, Military Medical Academy, Sofia, Bulgaria
DOI: https://doi.org/10.2478/amb-2020-0043 | Journal eISSN: 2719-5384 | Journal ISSN: 0324-1750
Language: English
Page range: 38 - 43
Accepted on: Dec 20, 2019
Published on: Nov 24, 2020
Published by: Sofia Medical University
In partnership with: Paradigm Publishing Services
Publication frequency: 4 issues per year

© 2020 V. Varbanova, A. Anastasova-Postadzhiyan, A. Nedeva, I. Nikolov, I. Kindekov, Y. Kuyumdzhieva, N. Petkova, E. Vikentieva, M. Lubomir, J. Raynov, published by Sofia Medical University
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.